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Abstract 
 
The non-receptor tyrosine kinase c-Src is frequently activated during 
progression of colon cancers. However, the molecular mechanisms underlying 
c-Src activation and c-Src–induced tumor progression remain to be elucidated. 
Previously, we showed that c-Src upregulation causes repression of a subset of 
miRNAs that target several genes implicated in tumor progression. In this study, 
I found that among these c-Src–regulated miRNAs, miR-27b is repressed not 
only by c-Src upregulation but also by activation of K-Ras/H-Ras. Inhibitor 
studies suggested that the PI3K pathway is involved in the repression of 
miR-27b, implicating miR-27b in a wider range of colon cancers. Indeed, 
miR-27b was repressed in various colon cancer cell lines and tumor tissues. 
Re-expression of miR-27b in human colon cancer HCT116 cells caused 
morphological changes, and suppressed tumor growth, cell adhesion, and 
invasive ability. I also identified ARFGEF1 and paxillin as novel targets of 
miR-27b, and found that miR-27b–mediated regulation of ARFGEF1 is crucial 
for controlling anchorage- independent growth, and that of paxillin is important 
for controlling cell adhesion and invasion. Furthermore, re-expression of 
miR-27b suppressed the activation of c-Src induced by integrin-mediated cell 
adhesion, suggesting that repression of miR-27b may contribute to c-Src 
activation in cancer cells. These findings demonstrate that miR-27b functions as 
a tumor suppressor by controlling ARFGEF1 and the paxillin/c-Src circuit at 
focal adhesions. 
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General Introduction 
 
Cancer 
Cancer is one of the leading causes of death worldwide. Cancer arises from 
normal cells by "the gain of function" and "the loss of function". In the gain of 
function, oncogenes are amplified and become constitutively active to acquire 
the cancer phenotypes, while in the loss of function, tumor suppressor genes are 
decreased or lost resulting in being unable to stop cell growth and 
differentiation(Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011).    
 Although numerous cancer drugs have been developed, the problems such 
as a side effect, recurrence of cancer and metastasis remain unsolved. Since 
more getting older, more risks of suffering cancer people have, the number of 
cancer patients is expected to continue to increase in an aging society. Thus, it is 
required to find new remedy and therapeutic targets of human cancers.  
 
c-Src 
c-Src, the cellular form of a Rous sarcoma virus gene v-src, is the first discovered 
proto-oncogene in vertebrate (review in (Martin, 2004)), and the product of c-Src 
gene is a non-receptor tyrosine kinase that plays a pivotal role in signal 
transduction leading to cell proliferation, differentiation, adhesion, migration 
and immune function(Brown and Cooper, 1996; Thomas and Brugge, 
1997)(Figure GI-1). 
 c-Src shares a highly conserved structure with a protein family called Src 
family kinases (SFKs), which includes eight member proteins: c-Yes, Fyn, c-Fgr, 
Lyn, Hck, Lck, Blk and c-Src itself. The structure of SFK consists of five 
functional domains: N-terminal domain, Src homology 3 (SH3) domain, SH2 
domain, Kinase domain (or SH1), and C-terminal domain(Brown and Cooper, 
1996; Thomas and Brugge, 1997).  N-terminal domain contains lipid 
modification signal: myristylation (in all SFKs) and palmitylation (in the all 
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except c-Src and Blk), which are important for membrane localization. SH3 
domain contains a core consensus sequence of X-P-X-X-P to bind proteins 
bearing proline rich region. SH2 domain also controls protein interactions by 
recognizing phosphotyrosine.  
 Tyr416 in kinase domain and Tyr527 (in chicken c-Src) in C-terminal 
domain play a crucial role for regulating c-Src activity(Okada, 2012). Normally, 
Tyr527 is phosphorylated by C-terminal Src kinase Csk(Cooper et al., 1986; 
Nada et al., 1991; Okada and Nakagawa, 1989) (Figure GI-1). The SH2 domain 
interacts with pY527 and this interaction keeps the kinase domain in a closed, 
inactive conformation(Xu et al., 1997; Young et al., 2001). In contrast, the 
dephosphorylation of pY527 by phosphatases causes activation of c-Src catalytic 
activity(Cartwright et al., 1987), and the following phosphorylation of 
auto-phosphorylation site Tyr416 allows c-Src to gain full activity. This balance 
between phosphorylation and dephosphorylation of c-Src is important for its 
function as a molecular switch.  
 Aside from the regulation by Csk and phosphatases, there are several 
mechanisms for c-Src activation. The proteins containing Src SH2 and SH3 
binding domain, such as phosphorylated forms of Focal adhesion kinase (FAK) 
and CRK associated substrate (Cas), bind to SH2 and SH3 domains to promote 
activation of c-Src by abolishing intramolecular inhibitory 
interactions(Nasertorabi et al., 2006; Playford and Schaller, 2004; Thomas et al., 
1998). In addition, growth factor signals through transmembrane tyrosine 
kinase receptors including platelet-derived growth factor receptor (PDGFR) and 
epidermal growth factor receptor (EGFR), and integrin-mediated cell adhesion 
signals also cause c-Src activation. These interactions are important for 
downstream signaling pathways, including MAPK, PI3K/Akt, STAT3 pathway, 
leading to cell proliferation and cell movements(Parsons and Parsons, 1997). 
 c-Src has been implicated in cancer (Figure GI-2): the expression and 
activity of c-Src are elevated with tumor progression in various human cancers, 
 6 
including colorectal, lung, breast, pancreatic and ovarian cancers (Frame, 2002; 
Yeatman, 2004), and the inhibitors of c-Src activity have entered clinical 
trials(Aleshin and Finn). Several studies have shown that ectopic expression of 
v-Src into normal cells is sufficient to induce transformation(Jove and Hanafusa, 
1987).  In contrast, c-Src has poor transforming ability, unless c-Src is 
overexpressed and/or mutated(Oneyama et al., 2008). However, c-Src mutation 
has been rarely seen in human cancer tissues(Daigo et al., 1999; Irby et al., 
1999; Laghi et al., 2001; Nilbert and Fernebro, 2000; Wang et al., 2000). Thus, 
the underlying mechanisms of c-Src deregulation in human cancer and how 
c-Src involves progression of cancer remain elusive.  
   
miRNA 
MicroRNAs (miRNA) are small non-coding, single-stranded RNAs of ~22 
nucleotides found in plants, invertebrate and vertebrate animals (Figure GI-3). 
 miRNAs are transcribed by RNA polymerase Ⅱ and are controlled by RNA 
pol Ⅱ-associated transcription fanctors and epigenetic regulators(Lee et al., 
2004). After the transcription, the primary miRNA (pri-miRNA), containing a 
long stem loop structure, goes thorough multi steps of maturation(Ha and Kim, 
2014; Lee et al., 2002). The nuclear RNase Ⅲ Drosha splices out the loop 
structure from pri-miRNA to release a small hairpin-shaped RNA of ~65 
nucleotides called pre-miRNA(Lee et al., 2003). Pre-miRNA is exported to the 
cytoplasm by exportin 5 (EXP5)(Bohnsack et al., 2004; Lund et al., 2004; Yi et al., 
2003) and is cleaved by Dicer(Hutvágner et al., 2001). The cleaved small RNA 
duplex ~22 nucleotides long, named miRNA/miRNA*, is loaded on Argonaute 
(AGO) proteins to form the RNA-induced silencing complex (RISC). Within the 
RISC, the dsRNA is unwound and the mature miRNA is selected to guide target 
recognition, while the complimentary strand miRNA* is subjected to 
degradation(Kawamata and Tomari, 2010). Finally, miRNA-RISC inhibits gene 
expression by translational repression, and/or mRNA degradation (Carthew and 
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Sontheimer, 2009). Since miRNAs recognize their targets with incomplete 
complementarity(Bartel, 2009; Lewis et al., 2005), miRNAs have a potential to 
target over one-third of human genes. Indeed, thorough the post-transcriptional 
repression of target genes, miRNA is involved in variety of biological functions 
including differentiation, development, immune system and survival(Baltimore 
et al., 2008; Carrington and Ambros, 2003; Kosik, 2006; Schickel et al., 2008; 
Wienholds and Plasterk, 2005). Conversely, deletion or incorrect expression of 
miRNAs leads to disease, including cancer. 
 Numerous reports have demonstrated that the aberrant expression of 
miRNAs is found in human cancers compared with normal tissues(Calin et al., 
2002; Huang et al., 2010; Iorio et al., 2005; Iorio et al., 2007; Lu et al., 2005; 
Porkka et al., 2007), and that miRNAs play an important role in controlling 
tumor growth and progression by regulating the gene expression of tumor 
suppressor and oncoproteins(He et al., 2007; Johnson et al., 2005; Ma et al., 
2010; Meng et al., 2007; Park et al., 2008; Zhang et al., 2007). For example, let-7, 
which is often downregulated in lung, breast and colon cancer, regulates tumor 
growth by targeting RAS oncogene(Johnson et al., 2005). Tumor suppressor 
PTEN expression is inhibited by miR-21, which is highly expressed in 
cancer(Meng et al., 2007). Thus, miRNAs or its antagonists have a potential to 
be a therapeutic target, and a prognostic and diagnostic biomarker. In addition 
to such benefit, analyzing the characteristic and molecular function of miRNAs 
contributes to clarify a new regulatory mechanism of oncogenic signaling 
pathways. 
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Introduction 
 
Number of colorectal cancer patients and its mortality are increasing all around 
the world. Malignant progression of colorectal cancer is induced via subsequent 
accumulation of genetic alterations, often including mutations in K-Ras, B-Raf, 
PI3K, and p53, as well as gains or losses of chromosomes(Walther et al.). In 
addition, the tyrosine kinase c-Src is often upregulated or activated during the 
progression of colon cancer(Frame, 2002; Iravani et al., 1998; Irby and Yeatman, 
2000; Talamonti et al., 1993; Walther et al.). However, despite the accumulation 
of genomic data on human cancers, mutations in the SRC gene have rarely been 
observed(Daigo et al., 1999; Irby et al., 1999; Laghi et al., 2001; Nilbert and 
Fernebro, 2000; Wang et al., 2000); therefore, the upregulation of c-Src (and the 
resultant contribution to cancer progression) is thought to result from 
dysregulation of c-Src expression or activity. 
 
Tyrosine kinase c-Src and cancer 
c-Src serves as a molecular switch that coordinately controls various cellular 
functions, including cell proliferation, adhesion, migration, invasion, and 
metastasis(Brown and Cooper, 1996; Thomas and Brugge, 1997). In the resting 
state, c-Src is inactivated through phosphorylation at the negative regulatory 
site Tyr527 by CSK(Nada et al., 1991). Upon stimulation with growth factors or 
extracellular matrix proteins, c-Src is activated and triggers downstream 
signaling pathways, including the Ras/MAPK, PI3K/Akt, and STAT3(Thomas 
and Brugge, 1997). Although the underlying mechanisms remain elusive, many 
studies have shown that the expression levels and specific activity of c-Src are 
elevated during the development of various human cancers, including lung, 
breast, prostate, and colon cancer(Summy and Gallick, 2003). To elucidate the 
molecular mechanisms underlying c-Src–induced transformation and its role in 
tumor progression, we developed a model system using Csk-/- mouse fibroblasts, 
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in which activated wild-type c-Src induces cell transformation(Oneyama et al., 
2008). Using this system, we have analyzed molecular events downstream of 
upregulated c-Src. 
 
MicroRNAs are regulator of cancer 
MicroRNAs (miRNAs) are endogenous small (~22 nucleotides) non-coding RNA 
that regulate gene expression by degrading and/or transcriptional inhibition of 
target mRNAs(Ambros, 2004; Bartel, 2004; Ventura and Jacks, 2009). 
Furthermore, miRNAs can recognize mRNAs with incomplete complementarity, 
increasing the set of genes that each miRNA can target(Lewis et al., 2005). Thus, 
miRNAs and their targets constitute a large genetic regulatory network linked 
to a wide range of cellular functions, including proliferation, differentiation, 
development, metabolism, and survival(Carrington and Ambros, 2003; 
Ivanovska et al., 2008; Kobayashi et al., 2008; Lee et al., 2005). Many studies 
have shown that miRNAs are aberrantly expressed in a substantial portion of 
human cancers, and that miRNAs play important roles in controlling tumor 
growth and metastasis through the post-transcriptional regulation of tumor 
suppressors and oncoproteins(Calin and Croce, 2006; Esquela-Kerscher and 
Slack, 2006; Lu et al., 2005). 
 
MicroRNAs involved in c-Src transformation 
Our previous results revealed that c-Src upregulation in Csk-/- MEF induces 
repression of a group of micro RNAs (miRNAs), including miR-99a, miR-542, 
miR-503, miR-322 (miR-424 in human), miR-27b, miR-23b, and 
miR-450a(Oneyama et al., 2011). Subsequent studies showed that miR-99a 
controls tumor growth by targeting mTOR and FGFR in human lung cancer, and 
that miR-542-3p targets integrin-linked kinase, resulting in the downregulation 
of cell adhesion and invasion of human colon cancer(Oneyama et al., 2012). In 
addition, the miR-503/-424 cluster strictly controls tumor progression by 
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targeting Rictor, one of the components of mTORC2(Oneyama et al., 2013). 
These findings suggest that specific miRNAs are involved in controlling tumor 
progression induced by c-Src upregulation. 
 To further extend our understanding of the role of miRNA in c-Src–
mediated tumor progression, I focused on determining the function of miR-27b, 
which is downregulated in human cancers, including colon, lung, breast, and 
prostate cancer(Navon et al., 2009; Taylor et al., 2010), suggesting that it may 
function as a tumor suppressor(Ishihara et al., 2014; Lee et al., 2012; Wan et al., 
2014). At present, the mechanisms underlying miR-27b downregulation, as well 
as the critical targets of this miRNA in human cancers, remain to be elucidated. 
 
 Here, I show that miR-27b expression is repressed not only by c-Src 
upregulation, but also by activation of K-Ras/H-Ras. miR-27b is also repressed 
in various human cancer cell lines and tumor tissues, implying that its 
expression is controlled downstream of a wide range of oncogenic signals. I also 
show that miR-27b directly targets ARFGEF1 and paxillin to suppress tumor 
growth and invasion in human colon cancers, and that miR-27b–mediated 
repression of paxillin attenuates focal adhesion–mediated signaling. The latter 
finding suggests that repression of miR-27b accounts for the activation of c-Src 
in human cancers. My results suggest that repression of miR-27b contributes to 
malignant progression of a wide range of human colon cancers, and raises the 
possibility that miR-27b serves as a prognostic marker in human colon cancers. 
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Results 
 
miR-27b expression is inhibited by c-Src induced transformation 
As I described, miR-27b expression was downregulated by c-Src induced 
transformation in Csk-/- MEF(Oneyama et al., 2011). To further confirm 
c-Src-mediated miR-27b downregulation, I employed Dox-inducible system of 
c-Src in Csk-/- MEF (Figure 1a). In this system, c-Src expression and its activity 
increase with Dox treatment as shown in Figure 1b. Total RNAs were collected 
after the indicated times of Dox addition, and subjected to quantitative real-time 
PCR (qRT-PCR). Figure 1c shows that miR-27b expression was decreased with 
c-Src upregulation, suggesting that c-Src controls the expression of miR-27b for 
its transformation activity. To explore the role of miR-27b in c-Src-mediated 
transformation, I induced miR-27b expression in Csk-/-/c-Src MEF and examined 
colony formation activity of the cells. Soft-agar colony-formation assay 
demonstrated that the number of colonies was decreased by miR-27b expression, 
suggesting that miR-27b suppresses c-Src-induced transformation (Figure 1d). 
 
miR-27b is downregulated in human colon cancer 
To figure out whether miR-27b is involved in transformation induced by the 
other oncogenes, I examined mouse embryonic fibroblasts (MEFs) transformed 
with v-Src, H-Ras, or K-Ras. qRT-PCR analysis revealed that miR-27b was 
significantly repressed by transformation induced by any of the oncogenes I 
tested, suggesting that miR-27b expression is controlled downstream of multiple 
oncogenic pathways involving Src and Ras (Figure 2a).  
 Next, I analyzed miR-27b expression in human colon cancer cell lines 
(Figure 2b). qRT-PCR analysis revealed that miR-27b levels were substantially 
reduced in HCT15, HCT116, and HT29 cells relative to those in normal cells 
(FHC), whereas SW480 and SW620 cells exhibited more moderate repression of 
miR-27b. I also observed repression of miR-27b in human prostate cancer cell 
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lines (Figure 2c).  
 Western blot analysis demonstrated that HCT15, HCT116, and HT29 cells, 
had higher levels of c-Src activity and protein, as well as activated Akt (Figure 
3a). By contrast, SW480 cells had lower levels of c-Src activity and protein, and 
SW620 cells exhibited specific reduction in Akt activity. These results suggest 
that expression levels of miR-27b correlate with the activation status of the c-Src 
and/or Akt. To identify pathways leading to the repression of miR-27b, I used 
dasatinib, U0126, and LY294002 to inhibit Src family kinases, the MAPK 
pathway, and the PI3K pathway, respectively. qRT-PCR analysis of HCT116 
and HT29 cells revealed that only LY294002 increased miR-27b expression 
(Figure 3b), suggesting that the PI3K/Akt pathway plays a role in the repression 
of miR-27b. Unexpectedly, inhibition of Src kinases with dasatinib did not affect 
miR-27b expression. This phenomenon might be explained by the fact that 
HCT116 and HT29 cells have activating mutations in PI3K: consequently, even 
though c-Src was inhibited, the constitutively-activated PI3K/Akt pathway 
repressed miR-27b expression. The inefficacy of MEK inhibitor U0126 further 
suggested that the Ras/PI3K pathway, rather than the Ras/MAPK pathway, is 
the primary cause of miR-27b repression. The same analysis on SW480 cells 
bearing K-Ras mutation and WT PI3K showed that LY294002 had no effect on 
miR-27b expression (Figure 3c). In addition, Dox-inducible constitutive active 
PI3K expression suppressed miR-27b in normal mammary epithelial cells, 
MCF10A (Figure 3d). These observations raise the possibility that the PI3K/Akt 
pathway, which can be activated downstream of c-Src and/or Ras, contributes 
significantly to repression of miR-27b in human cancers. 
 Because mutations in K/H-Ras and PI3K are frequently detected in 
human colon cancers, it is likely that miR-27b is repressed in a wide range of 
colon cancer tissues. I revealed that the level of miR-27b expression was 
markedly decreased in tumors from 9 out of 10 patients, relative to the level in 
adjacent normal tissues (Figure 4). These results suggest that expression of 
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miR-27b is repressed in a wide range of human cancers, potentially through the 
Src/Ras/PI3K pathway. 
 
miR-27b inhibited tumor growth of human colon cancer cells 
To evaluate the role of miR-27b in human cancers, I investigated whether 
miR-27b would suppress tumor growth of human colon cancer cells. Soft-agar 
colony-formation assays showed that re-expression of miR-27b markedly 
decreased the number of colonies in HCT116 and HT29 (Figure 5a), but was less 
effective in SW480 cells, which express miR-27b at higher levels than other cell 
types (Figure 2b). These growth-suppressive effects were also observed in 
prostate cancer cells (Figure 5b). Re-expression of miR-27b grossly suppressed 
tumorigenicity of HCT116 cells in nude mice (Figure 5c). Thus, miR-27b has the 
potential to suppress tumor growth of human colon cancer cells both in vitro and 
in vivo. 
 
miR-27b suppresses cell adhesion and invasion of human cancer  
Next, the effects of miR-27b re-expression on the cell morphology and 
invasiveness of HCT116 (colone) and DU145 (prostate) cells were examined. 
Transfection of miR-27b caused morphological changes to the spindle-like shape 
(Figure 6a and 6b, left). Notably, staining for F-actin and vinculin (universal 
focal adhesion maker) revealed that miR-27b transfection suppressed the 
formation of focal adhesions (Figure 6a and 6b right). It is known that c-Src 
localizes focal adhesions to transduce extracellular signals to its downstream 
substrates. Figure 7a show that the localization of pY418 to focal adhesions was 
reduced by miR-27b re-expression in HCT116 cells. In DU145 cells, miR-27b 
also interfered the localization of pY418 to invadopodia (white arrow), which is 
an important structure for degrading extracellular matrix and subsequent cell 
invasion and metastasis (Figure 7b).  
 Because focal adhesions are crucial for cell adhesion, motility, and 
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invasion, I tested whether miR-27b would inhibit adhesion and invasion in these 
cells. Assays on fibronectin-coated plates revealed that miR-27b induced a 
significant decrease of adhered cells (Figure 8a). In addition, Matrigel assays 
revealed that miR-27b significantly suppressed the invasive activity of HCT116 
cells (Figure 8b). I observed similar effects of miR-27b on cell invasion in DU145 
prostate cancer cells (Figure 8c). 
 To confirm the role of miR-27b in cancer cells, I introduced anti-miR-27b 
into HCT116 cells, in which miR-27b is still expressed, albeit at a modest level. 
Colony formation and Matrigel invasion assays revealed that inhibition of 
miR-27b significantly promoted anchorage-independent cell growth (Figure 9a) 
and invasive activity (Figure 9b). These findings suggest that miR-27b has the 
ability to suppress tumor growth and progression in human cancers. 
 
miR-27b targets paxillin/ARFGEF1/Rab14/ADAM19 
To explore the mechanisms of miR-27b-mediated tumor suppression, I searched 
potential targets of miR-27b in human genes using the TargetScan 
(http://www.targetscan.org/). Since miR-27b suppressed cell adhesion and 
invasion, I chose 20 genes related to cell adhesion and invasion from the 
predicted genes. The 3'UTR fragments (~50bp) around the predicted targeting 
site of miR-27b were inserted to pMIR-report control vector and validated by 
luciferase reporter assay in c-Src–transformed cells.  The luciferase activities of 
constructs containing the predicted target sites of paxillin, ARFGEF1, Rab14, 
and ADAM19 were significantly reduced in miR-27b transfected cells (Figure 
10a). The miR-27b–mediated reduction of luciferase activities was abolished by 
mutation of the recognition sites, confirming that miR-27b interacts specifically 
with these target sequences. Consistent with the results of the luciferase assays, 
Western blot analysis revealed that paxillin, ARFGEF1, Rab14, and ADAM19 
protein levels were decreased by miR-27b treatment of human cancer cells 
(Figure 10b). Conversely, anti-miR-27b increased the levels of these proteins 
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(Figure 10c). These findings suggest that miR-27b suppresses tumor growth and 
progression by targeting multiple genes related to cell adhesion and invasion. 
 
miR-27b–mediated regulation of ARFGEF1 expression is crucial for tumor growth 
Although these candidate targets appear to have different functions, they are all 
potentially required for the creation of dynamic cell movements. Paxillin is a 
component of the focal adhesion complex, which links extracellular matrix to 
F-actin in cells(Burridge et al., 1992). ARFGEF1 is the guanine-nucleotide 
exchange factor for the ADP ribosylation factors ARF1 and ARF3, which play 
important roles in membrane trafficking(Moss and Vaughan, 1995; Togawa et 
al., 1999). Rab14 is also involved in membrane trafficking, especially between 
the Golgi complex and endosomes; in particular, it transports ADAM10 and 
FGFR, which are involved in the regulation of cell–cell junctions and embryonic 
development(Junutula et al., 2004; Linford et al., 2012; Ueno et al., 2011). 
ADAM19, a member of the A Disintegrin And Metalloproteinase (ADAM) family 
of proteins, promotes shedding of growth factors and cytokines, such as 
neuregulin(Shirakabe et al., 2001; Wei et al., 2001).  
 To elucidate the roles of these targets in cancer-related phenotypes, I used 
shRNAs to knock down paxillin, ARFGEF1, Rab14, and ADAM19 in HCT116 
cells (Figure 11a). Soft-agar colony-formation activity was suppressed by 
knockdown of paxillin or ARFGEF1, but not Rab14 or ADAM19 (Figure 11b). 
Notably, ARFGEF1 knockdown decreased the number of colonies significantly, 
to a level comparable with that in miR-27b–transfected cells (Figure 5a). Similar 
results were obtained in HT29 and DU145 cells (Figure 11c). Re-expression of 
ARFGEF1 rescued the colony-forming activity of the ARFGEF1 knockdown cells, 
confirming that suppression of tumor growth by sh-ARFGEF1 is not due to an 
off-target effect (Figure 11d). Furthermore, overexpression of ARFGEF1 
restored colony formation of cells transfected by miR-27b (Figure 11e). Taken 
together, these results suggest that ARFGEF1 is crucial for controlling tumor 
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growth and that repression of ARFGEF1 largely contributes to the miR-27b–
mediated growth suppression. 
 ARF1, the target of ARFGEF1, promotes activation of Akt and ERK1/2 in 
breast cancer(Boulay et al., 2008). In addition, ARFGEF1 promotes activation of 
Akt and ERK1/2 in neuronal cells(Zhou et al., 2013). Consistent with these 
findings, when cells were cultured on non-adherent poly-HEMA coated dishes, 
the levels of the active form of Akt (pAkt) were reduced in ARFGEF1-knockdown 
cells, as well as in miR-27b–transfected cells (Figures 12a and 12b). However, 
re-expression of ARFGEF1 did not attenuate the suppression of pAkt caused by 
miR-27b (Figure 12c), suggesting that another downstream target of ARFGEF1, 
which is responsible for tumor growth, remains to be identified. 
 
miR-27b–mediated regulation of paxillin is important for cell adhesion and invasion 
I next examined the roles of paxillin, ARFGEF1, Rab14, and ADAM19 in 
determining cancer cells’ capacity for cell adhesion and invasion. Knockdown 
studies revealed that paxillin knockdown significantly attenuated focal adhesion 
formation, cell adhesion and invasion in HCT116 cells (Figures 13, 14a and 14b). 
As mentioned above, miR-27b caused morphological changes and reduced the 
number of focal adhesions, concomitant with suppression of cell adhesion and 
invasive activity, in HCT116 cells (Figure 6 and 8). However, overexpression of 
paxillin in miR-27b–treated cells reversed the morphological changes (Figures 
15b and 15c) and restored cell adhesion and invasion (Figures 16a and 16b). 
These findings suggest that paxillin is a target of miR-27b responsible for 
controlling cell adhesion and invasive potential in cancer cells. 
 
miR-27b inhibits oncogenic signaling stimulated by cell adhesion 
Focal adhesions are dynamic multi-protein/membrane structures that connect 
intracellular F-actin and extracellular matrix (ECM) through integrins. Cells 
attach to ECM and migrate via a cycle of formation and degradation of focal 
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adhesions. Paxillin is a crucial component of the focal adhesion complex, serving 
as a platform on which tyrosine kinases such as c-Src and FAK are 
activated(Schaller, 2001). 
 To determine whether miR-27b regulates the activity of c-Src by 
regulating paxillin, I stimulated HCT116 cells by integrin-mediated cell 
adhesion. In the cells transfected with cont-miR, c-Src was activated at sites of 
cell adhesion. By contrast, activation of c-Src was suppressed in miR-27b–
transfected cells (Figures 17a and 17b). Furthermore, activation of ERK1/2 and 
FAK, a downstream signaling component, was also suppressed by miR-27b, 
indicating that miR-27b may negatively regulate c-Src signaling evoked by 
integrin-mediated cell adhesion. 
 
miR-27b hostgene APO suppresses tumor cell growth and migration 
MicroRNAs are located in various genomic loci. Most mammalian miRNA genes 
are located in defined transcription units(Hinske et al., 2010; Kim and Nam, 
2006; Rodriguez et al., 2004). The location of some intronic miRNAs is well 
conserved among diverse spices. For example, miR-106b~25 is located in the 
intron of MCM7 in both human and mice, and miR-1306 is found in the locus of 
DGCR8. Interestingly, some intronic miRNAs, not only are transcribed together, 
but also functionally interact with their host genes(Barik, 2008; Lund, 2010; 
Poliseno et al., 2010). 
 miR-27b cluster (miR-23b~27b~24b) is located in the intron of 
Amino-peptidase O (APO) in human, mouse and chicken. APO is a member of 
the M1 metalloproteinase family. APO is highly conserved, however, the 
function of APO in cancer and the functional association between APO and 
miR-27b remains to be elucidated. 
 To address this question, I analyzed APO expression using Csk-/- MEF in 
which c-Src is inducible by DOX treatment. PCR analysis demonstrated that the 
expression level of APO mRNA decreased by c-Src overexpression (Figure 20a), 
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which was almost same kinetics as miR-27b (Figure 1c), implying that APO is a 
candidate for a tumor suppressor. qRT-PCR analysis, however, revealed that 
APO mRNA is upregulated in breast cancer cell lines, T47D, MCF7 and 
MDA-MB-231 cells, compared to that in normal breast epithelial MCF10A cells 
(Figure 20b). Subsequent analysis for APO protein expression showed that APO 
is only expressed in MDA-MB-231 among the cell lines I tested (Figure 20c). 
Since MDA-MB-231 cells are classified as triple negative breast cancer cell line, 
whereas T47D and MCF7 are moderate luminal breast cancer cells, I 
hypothesized APO may promote tumor progression. To examine whether APO 
upregulation leads to acquisition of malignant phenotype, I tested 
colony-forming ability and cell migration ability of the APO overexpressed 
MCF7 cells. Interestingly, APO overexpression suppressed both phenotypes 
(Figure 20d and 20e). This result, however, is not consistent with the fact that 
APO was highly expressed in malignant MDA-MB-231 cells; hence further 
analysis using other types of cancers is required. 
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Discussion 
  
In this study, I showed that activation of the oncogenic c-Src/Ras/PI3K pathway 
induces repression of miR-27b, which plays a tumor-suppressive role in human 
colon cancer cells. miR-27b directly targets ARFGEF1 and paxillin, which are 
required for tumor growth and cancer cell adhesion/invasion, respectively. 
Therefore, I postulate that miR-27b–mediated upregulation of ARFGEF1 
contributes to tumor growth by activating the ARFGEF1/Akt pathway, and that 
paxillin upregulation promotes formation of focal adhesions, resulting in the 
activation of cell motility and invasive/metastatic potential (Figure 8). 
 Cancer cells accumulate mutations in proto-oncogenes and tumor 
suppressors, including K-Ras, TP53, and PI3K during tumor progression. We 
showed that miR-27b is downregulated by transformation by not only c-Src/v-Src, 
but also K-/H-Ras and PI3K. These results suggest that aberrant expression of 
miR-27b may be a relatively early event in cancer progression. 
Bioinformatic analysis of prostate cancer has shown that miR-27b is 
significantly downregulated in primary tumors, and this downregulation 
becomes more remarkable in metastatic tumors (Figure 18). These observations 
raise the possibility that miR-27b could be useful as a prognostic marker in 
human cancers. 
 ARFGEF1 localizes to the trans-Golgi network and activates the class I 
ADP ribosylation factors, ARF1 and ARF3, by promoting GDP–GTP exchange to 
initiate membrane vesicle formation. ARF1, which plays a role in vesicular 
trafficking(D'Souza-Schorey and Chavrier, 2006) is upregulated in invasive 
breast cancers and gastric cancers(Boulay et al., 2011; Tsai et al., 2012); it 
promotes the activation of PI3K/Akt pathway and retinoblastoma protein, 
thereby promoting cell proliferation, migration, and invasion in breast cancer 
cells(Boulay et al., 2008; Boulay et al., 2011). ARFGEF1 is also involved in cell 
adhesion and migration by regulating proper glycosylation and function of 
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integrin β1. These facts implicate ARFGEF1/ARF1 in the progression of cancer 
phenotypes; to date, however, the direct link between ARFGEF1 and cancer has 
not been addressed. In this study, I found that depletion of ARFGEF1 
significantly suppresses tumor growth of human cancer cells. This is the first 
evidence for a contribution of ARFGEF1 to cancer, suggesting that ARFGEF1 
represents a novel therapeutic target for human cancer. 
 Focal adhesions connect between the extracellular matrix and 
intercellular F-Actin to control cell morphology, adhesion, and motility, which 
are important for cancer invasion and metastasis. Upon cell adhesion via 
integrins, paxillin is heavily phosphorylated by c-Src and FAK, creating a 
platform for adaptor proteins that activate downstream intracellular signaling, 
thereby promoting cell growth and survival. Paxillin is upregulated in various 
human cancers and involved in tumor malignancies. Previously, however, the 
molecular connections between upregulated paxillin and downstream effectors, 
such as c-Src, and the mechanisms underlying paxillin upregulation remained 
unclear. In this study, I showed that repression of miR-27b by oncogene 
activation causes upregulation of paxillin. This upregulation may lead to 
elevated activation of c-Src signaling delivered from focal adhesions, resulting in 
the promotion of cancer malignant phenotypes, i.e., invasion and metastasis. 
 In colon cancers, c-Src activity is elevated with the progression of cancer 
stages, implying that the protein plays a role in malignant progression, i.e. the 
acquisition of invasive and metastatic phenotypes. However, in contrast to other 
oncogenes such as K-Ras and PI3K, mutations in the SRC gene are rarely 
detected. In this study, I proposed a new mechanism for the upregulation of 
c-Src activity: upregulation of paxillin via downregulation of miR-27b. Recent 
work showed that c-Src is directly targeted by miR-23b, a tumor suppressor that 
is silenced by methylation in prostate cancer(Majid et al., 2012). miR-23b and 
miR-27b are encoded by the same gene cluster, miR-23b/27b/24-2, located in the 
last intron of the aminopeptidase O gene, suggesting that expression of both 
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miR-23b and miR-27b is regulated through a common pathway. Indeed, I 
observed that the expression of miR-23b was repressed by c-Src–induced 
transformation with the same kinetics as miR-27b (unpublished data). If this is 
the case in human cancers, it is possible that the miR-23b/27b/24-2 cluster 
regulates c-Src via dual mechanisms: regulation of the c-Src kinase activity via 
indirect upregulation of paxillin, and direct regulation of the c-Src protein level 
by miR-23b. Because the expression of miR-27b is regulated downstream of c-Src 
(Figure 19), upregulation of c-Src may further amplify the positive-feedback loop 
mediated by the miR-23b/27b/24-2 gene cluster, thereby promoting tumor 
malignancy mediated by c-Src activity. This model may account for the frequent 
upregulation of c-Src in various human cancers. 
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Conclusions 
 
In this study, I analyzed the function of miR-27b in cancer, which expression is 
downregulated by c-Src-induced transformation. The results showed that 
miR-27b was downregulated in human colon cancer cells and tissues as well as 
in prostate cancer cells, and that ectopic expression of miR-27b caused 
morphological chages and significantly suppressed cell growth and invasion of 
the cancer cells. I identified novel targets of miR-27b; paxillin, ARFGEF1, Rab14 
and ADAM19. Since each miRNA can target multiple genes, miRNA composes a 
complex signaling crosstalks and it is challenging to figure out which target is 
most important. The knockdown and rescue experiments of miR-27b target 
genes revealed that inhibition of ARFGEF1 and paxillin expression are crucial 
for its function as a tumor suppressor. In addition, miR-27b inhibited activation 
of c-Src and the subsequent downstream signaling caused by integrin-mediated 
cell adhesion. This finding suggests a new regulatory mechanism for the 
elevation of c-Src activity with cancer progression: c-Src and the related 
oncogenic pathway inhibit miR-27b expression, followed by the overexpression of 
paxillin, leading to the stabilization of focal adhesion, the enhancement and 
maintenance of its activity.  
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Materials and methods 
 
Cell culture 
All cells were cultured at 37°C in a humidified atmosphere containing 5% CO2. 
The human colon cancer cell lines, SW480, HCT116, and HT29, were purchased 
from the American Type Culture Collection (ATCC). Cells were maintained in 
Dulbecco's Modified Eagle's Medium (SW480 and HT29) or McCoy's 5A Modified 
Medium (HCT116) supplemented with 10% (v/v) fetal bovine serum (FBS) and 
penicillin–streptomycin (Nacalai Tesque, Kyoto, Japan). 
 
qRT-PCR analysis for miRNA 
Snap-frozen colon tissues were divided visually into tumor (T) and 
non-cancerous (N) regions that were then confirmed histologically. The research 
protocol for the collection of human samples was approved by the ethical review 
board of the Graduate School of Medicine, Osaka University, Japan. Informed 
consent was obtained from all patients in writing before enrollment in the study. 
Total RNA was isolated from cells and tissues using Sepasol (Nacalai Tesque). 
Total RNA was reverse transcribed using the TaqMan MicroRNA Reverse 
Transcription kit (Applied Biosystems, Bedford, MA, USA). The resultant cDNA 
samples were mixed with THUNDERBIRD Probe qPCR mix (TOYOBO, Osaka, 
Japan), and quantitative real-time PCR analysis was performed using ABI 
PRISM 7900HT (Applied Biosystems). The following TaqMan MicroRNA Assays 
were used: hsa-miR-27b, 000409; snoRNA202, 001232; and RNU48, 001006. 
 
miRNA transfection 
miR-27b precursor (PM10750) and antisense miR-27b (AM10750) were 
purchased from Applied Biosystems. miRNA precursors or antisense miRNAs 
were transfected using Lipofectamine RNAi MAX (Invitrogen, Carlsbad, CA, 
USA). Forty-eight hours after transfection, cells were harvested using 
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Trypsin/EDTA and subjected to soft-agar colony-formation, adhesion, or 
invasion assays. 
 
Knockdown of miR-27b target genes by shRNA 
Knockdown of paxillin, ARFGEF1, Rab14, or ADAM19 was carried out using 
lentiviral vectors. Empty vector and vectors carrying sh-paxillin (NM_002859), 
sh-ARFGEF1 (NM_006421), sh-Rab14 (NM_016322), and sh-ADAM19 
(NM_023038) were purchased from Sigma–Aldrich (Milan, Italy). Lentiviruses 
were generated from PLT cells (ectopic retrovirus packaging cell line), using 
MISSION Lentiviral packaging mix (Sigma–Aldrich) and FuGENE HD (Roche, 
Mannheim, Germany). 
 
Retroviral and lentiviral transfection 
Mouse paxillin (NM_011223.2) containing mutations in the seed region of 
miR-27b and mouse ARFGEF1 (NM_001102430.1) was subcloned into 
pCX4-puro vector. pCX4-puro-paxillin was transfected into PLT cells (ecotropic 
retrovirus packaging cell line) using FuGENE HD (Roche). 
pCX4-puro-ARFGEF1 was transiently transfected into HCT116 cells using 
Lipofectamine LTX. 
 
Immunohistochemistry 
Cells (5 × 104) were seeded on a 15 mm coverslip coated with 2 µg/ml fibronectin 
(Sigma–Aldrich) for 3 hr at room temperature. The samples were fixed in 4% 
paraformaldehyde (PFA, Sigma–Aldrich) at 37°C, for 10 min. After washing the 
samples twice with PBS for 10 min each, the cells were permeabilized with 
0.03% Triton-X in PBS (T-PBS) for 20 min. The samples were treated with 1% 
BSA in T-PBS for 30 min to block non-specific binding of the antibodies, and 
then washed with T-PBS for 5 min. The diluted antibody in T-PBS was added to 
each well, and the samples were incubated overnight at 4°C. After the samples 
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were washed four times for 10 min each with T-PBS, the samples were 
incubated with secondary antibody in T-PBS for 2 hr at room temperature in the 
dark. Phalloidin (to label F-Actin) was added with the secondary antibody. After 
washing the samples four times with T-PBS, coverslips were mounted on glass 
slides using Prolong Gold (Invitrogen). The next day, the coverslips were sealed 
with nail polish and subjected to observation under a confocal microscope 
(FV1000, OLYMPUS, Tokyo, Japan). 
 
Invasion assay 
BioCoat Matrigel Invasion Chamber (BD Biosciences, San Jose, CA, USA) was 
used for the invasion assay. Cells (5!×!104) were seeded on an insert and moved 
into a chamber containing culture supernatant of NIH3T3 cells. After incubation 
at 37°C for 48 hr, invaded cells were fixed with 100% methanol for 10 min and 
then stained with 0.1% toluidine blue (Chroma-Gesellschaft Schmid GmbH & 
Co) for 10 min. Invaded cells were counted on micrographs; in each experiment, 
cells were counted on five randomly chosen fields. 
 
Western blot 
Total cell lysates were isolated with 2×SDS sample buffer and boiled for 10 min. 
The samples were separated by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis and transferred onto a nitrocellulose or a PVDF membrane. The 
membrane was blocked with 1% BSA + 0.1% Tween 20 in TBS at room 
temperature for 30 min, and then incubated overnight at 4°C with the indicated 
primary antibodies. After two washes with T-TBS for 10 min each, the 
membrane was incubated with secondary antibodies in T-TBS with 1% BSA + 
5% skim milk. After three washes with T-TBS for 10 min each, blots were 
visualized using an ECL detection kit (Immuno zeta, Wako, Osaka, Japan) on 
X-ray film (Fujifilm, Tokyo, Japan). The following antibodies were used for 
western blots: anti-paxillin (BD), anti-ARFGEF1 (Bethyl, Montgomery, TX, 
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USA), anti-Rab14 (Abcam), anti-ADAM19 (Abcam, Cambridge, UK), anti–c-Src 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Src pY418 (Invitrogen), 
anti-FAK-pY397 (Invitrogen), anti-FAK (Santa Cruz Biotechnology), 
anti-GAPDH (Santa Cruz Biotechnology), anti-pERK1/2 (Cell Signaling, 
Danvers, MA, USA), anti-ERK1/2 (Cell Signaling), anti-pAkt (Cell Signaling), 
and anti-Akt (Cell Signaling). 
 
Luciferase reporter assay 
Putative targets of miR-27b were predicted using TargetScan. Approximately 50 
bp of 3'UTR containing the putative recognition site for miR-27b was 
synthesized and cloned into the pMIR-REPORT vector (Applied Biosystems), 
downstream of the firefly luciferase reporter gene. pRL-TK reporter vector 
(Applied Biosystems) was used as an internal control. These constructs and 
miRNA precursors were transfected into Csk-/-/c-Src cells seeded in 24-well 
plates, using Lipofectamine 2000 (Invitrogen). Sixteen hours after transfection, 
luciferase activities were measured using the PicaGene Dual Sea Pansy 
Luminescence Kit (Wako). 
 
In vivo tumorigenicit 
Cells (2!×!106 in 200 µl of serum-free medium) were subcutaneously injected into 
nude mice (BALB/cAJcl-nu/nu) purchased from Japan SLC, Inc. Tumor length 
(L) and width (W) were measured every 2–3 days. Tumor volume was evaluated 
using the mathematical formula V = 0.5 × L × W2. All animal experiments were 
conducted in accordance with the protocols approved by the Animal Research 
Committee of Research Institute for Microbial Diseases in Osaka University.  
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Figure GI-1. c-Src plays a critical role as a molecular switch
Normally, c-Src is inactivated thorough the phosphorylation by its negative regulator Csk. 
Once activated, c-Src regulates multiple signaling pathways leading to cell proliferation, 
differentiation, adhesion and migration.
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Figure GI-2. c-Src is highly expressed and activated in human cancer
Expression and activity of c-Src are associated with tumor progression, implicating that its 
pivotal role in cancer. However, the underlying mechanisms how c-Src is deregulated and its 
role in tumor progression remain unclear.
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Figure GI-3. MicroRNA regulates gene expression 
MicroRNAs (miRNAs) are small non-coading RNAs found in both animals and plants. 
miRNAs are transcribed by RNA polymerase , processed by Drosha and Dicer, and loaded 
on AGO proteins to form RISC. miRNA-RISC complex inhibits gene expression by 
translational repression and/or mRNA degradation.
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Figure 1. miR-27b expression is inhibited by c-Src induced transformation
(a) Schematic of c-Src-inducible system by DOX treatment. (b) Western blot for c-Src 
expression and its activity of the cells indicated in (a). Total cell lysates were collected at the 
indicated time poits after Dox treatment. (c) Expression levels of miR-27b in (b) Expression 
levels were assessed by qRT-PCR and normalized against Sno.  (d) miR-27b inhibited colony 
formation of the cells transformed by c-Src (Csk-/-/c-Src MEF). Csk-/-/c-Src cells were 
transfected with 30nM of cont-miR or miR-27b. After 48 hr transfection, soft agar colony 
formation assay was performed.
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Figure 2. miR-27b expression is downregulated in human cancer
(a) miR-27b expression levels in MEFs transfected with v-Src, H-Ras, K-Ras. (b) Expression levels 
of miR-27b in human colon cancer cells (HCT15, HCT116, HT29, SW480, and SW620) and in 
normal human colon epithelial cells (FHC). (c) Expression levels of miR-27b in human prostate 
cancer cell lines (DU145, LNCaP, and PC3) were compared with those in normal human prostate 
epithelial cells (PNT1A and PNT2). Expression levels were assessed by qRT-PCR and normalized 
against RNU48. (a-c) ***P<0.001
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Figure 3. PI3K/Akt pathway regulates miR-27b expression
(a) Western blot analysis of expression and activity of c-Src and Akt. (b) Inhibition of the PI3K 
pathway by LY294002 upregulated miR-27b expression in HCT116 and HT29 cells. Total RNAs 
were isolated 48 hr after. (c) Inhibition of PI3K by LY294002 had no effect on miR-27b expression 
in SW480 cells.  (d) qRT-PCR analysis for miR-27b in MCF10A cells expressing PI3KH1047R by 
using Retro-X Tet-On 3G Inducible Expression System. MCF10A cells stably expressing pRetroX-
Tet3G vector and pRetroX-TRE3G-PI3KH1047R were treated with Doxycycline (1µg/ml final) and 
total RNAs of the cells were collected after the indicated time. (b-d) **P < 0.01, ***P<0.001
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Figure 4. miR-27b is downregulated in human colon cancer tissues
Expression levels of miR-27b in human colon cancer tissues. Total RNAs were 
isolated from the cancer tissue (black bar) and the adjacent normal tissue (white bar).  
***P<0.001
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Figure 5. miR-27b suppresses tumor growth in human colon cancer cells in vitro and in vivo 
Effect of miR-27b on anchorage-independent growth of colon cancer cells (a) and prostate cancer 
cells (b). The cells transfected with 30 nM of cont-miR or miR-27b were subjected to colony-
formation assay 2 days after. Colonies stained with MTT were counted on micrographs. *P < 0.05, 
**P < 0.01. (c) miR-27b inhibited tumorigenicity of HCT116 in nude mice. Cells transfected with 
30 nM of cont-miR or miR-27b were injected into nude mice. 
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Figure 6. miR-27b causes morphological changes in human cancer. 
Effect of miR-27b on morphology of HCT116 cells (a) and DU145 cells (b).  
Left: optical microphotographs of cells transfected for 48 hr with 30 nM of cont-
miR or miR-27b. Right: analysis of stress fibers (F-actin; green) and focal 
adhesions (Vinculin; red). Scale bar; 10 µm. 
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Figure 7. miR-27b suppressed c-Src localization to focal adhesions. 
Effect of miR-27b on morphology of HCT116 cells (a) and DU145 cells (b).  
Analysis of stress fibers (F-actin; green) and active-c-Src localization (pY418; 
red). Scale bar; 10 µm. Arrow heads indicate focal adhesion, white arrows 
indicate invadopodia.
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Figure 8. miR-27b suppressed cell adhesion and invasion of cancer cells. 
(a) Effect of miR-27b on cell adhesion. HCT116 cells were transfected with 30 nM of cont-
miR or miR-27b for 2 days. Cells were plated onto fibronectin-coated dishes and adherent 
cells were counted. **P < 0.01.  (b) Effect of miR-27b on cell invasion. HCT116 cells were 
transfected with 30 nM of cont-miR or miR-27b for 2 days, and seeded into a Matrigel-
coated invasion chamber. 48 hours later, invaded cells were counted. (c) Invasion assay on 
DU145. **P < 0.01.  
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Figure 9. Inhibition of miR-27b enhances cell adhesion and invasion of cancer cells. 
Functional inhibition of miR-27b. HCT116 cells were transfected with 5 nM of anti-cont-miR or anti-
miR-27b for 2 days, and subjected to colony formation assay (a) and invasion assay (b). **P < 0.01.
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Figure 10. miR-27b directly targets paxillin, ARFGEF1, Rab14, and ADAM19. 
(a) The pMIR-Luc plasmid containing the wild-type or mutated (mt) 3'-UTR of each target 
was co-transfected into Csk-/-/c-Src cells with 30 nM cont-miR or miR-27b. The data are 
shown as means ± s.d. from three independent experiments.  (b) Western blot analysis for 
colon cancer cells transfected with 30 nM of cont-miR or miR-27b. (c) Inhibition of miR-27b 
increased protein levels of the targets. HCT116 cells transfected with anti-cont-miR or anti-
miR-27b (5 nM) were analyzed.
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Figure 11. ARFGEF1 is crucial for tumor growth.
(a) Knockdown of miR-27b target in HCT116 cells by each shRNA.  (b) Effect on anchorage-
independent growth of (a). *P < 0.05, **P < 0.01. (c) Effect of ARFGEF1 knockdown on colony 
formation in HT29 and DU145 cells. *P < 0.05, **P < 0.01. (d) Restoration of ARFGEF1 
expression rescued colony formation of ARFGEF1-depleted HCT116 cells. *P < 0.05, n.s.; no 
significance. (e) Overexpression of ARFGEF1 attenuated the inhibitory effect of miR-27b on 
colony formation in HCT116 cells. *P < 0.05
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Figure 12. ARFGEF1 is involved in Akt pathway.
(a) Western blot analysis for the activation of Akt in miR-27b transfected cells. HCT116 
cells transfected with 30 nM cont-miR or miR-27b for 48 hr were plated on poly-HEMA 
coated dishes and incubated for 12 hr. (b, c) Analysis of the promotion of Akt activation 
by ARFGEF1. The cells indicated in (Figure 11d and 11e) were plated on poly-HEMA–
coated dishes and lysates were immunoblotted. 
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Figure 13. Paxillin promotes focal adhesion formation.
Effect of sh-RNAs on morphology of HCT116 cells.  
Left: optical microphotographs of cells. Right: analysis of stress fibers 
(F-actin; green) and focal adhesions (Vinculin; red). Scale bar; 10 µm. 
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Figure 14. Paxillin is crucial for cell adhesion and invasion.
(a) Effect of knockdown of each target on cell adhesion in HCT116 cells. The 
indicated cells were plated on collagen-coated dishes and attached cells were 
counted. **P < 0.01.  (b) Effect of knockdown of each target on cell invasion. 
**P < 0.01. 
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Figure 15. Overexpression of Paxillin reverses morphological changes caused by miR-27b 
(a) Paxillin overexpression in HCT116 cells. Cells containing mock vector or paxillin expression vector 
were transfected with 30 nM cont-miR or miR-27b. (b) Optical micrographs of the cells indicated in (a). (c) 
HCT116 cells with mock vector or paxillin were transfected with 5 nM of cont-miR or miR-27b, and then 
subjected to immunostaining for focal adhesions (red) and F-Actin (green). Scale bar: 10 µm. 
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Figure 16. Paxilin expression is crucial for suppression of 
cell adhesion and invasion by miR-27b.
Cell adhesion (a) and invasion (b) were rescued by overexpression 
of paxillin. Cells indicated in (Figure 15a) were subjected to assays. 
**P < 0.01.
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Figure 17. miR-27b suppresses c-Src activation stimulated by cell adhesion.
(a) HCT116 cells were transfected with 30 nM of cont-miR or miR-27b for 2 days, detached, 
and incubated in serum-free media at 37°C for 30 min. These cells were plated on 
fibronectin-coated dishes, and the cell lysates of attached cells obtained at the indicated time 
points were immunoblotted. (b) Quantitation of c-Src (pY418), FAK (pY397), and ERK1/2 
activation. Data presented are shown as means ± s.d. from three independent experiments.  
*P < 0.05, **P < 0.01.
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Figure 18. In silico analysis for miR-27b and its targets expression in human prostate 
cancer tissues.
Microarray data sets, previously published by other groups, were downloaded from the NCBI GEO 
Data Portal (GSE21036 and GSE6752) and reanalyzed. GSE21036 contains the microRNA expression 
data for human primary and metastatic prostate cancer samples and control normal adjacent benign 
prostate, analyzed using Agilent microRNA V2 arrays. GSE6752 contains CodeLink Expression Data 
from primary prostate tumor and prostate tumor metastases, analyzed using Affymetrix 
oligonucleotide arrays. (a) Expression of miR-27b in normal prostate, primary tumor and metastasized 
tumor. (b) Expression of paxillin, ARFGEF1, Rab14, and ADAM19 in primary prostate tumor and 
metastatic tumor.
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Figure 19. miR-27b mediated regulation of tumor progression
In normal cells expressing miR-27b, expression of paxillin and ARFGEF1 is limited 
to avoid unregulated cell growth and/or motility. Once miR-27b expression is 
downregulated due to activation of the Ras/Src/PI3K pathway, expression of paxillin 
and ARFGEF1 is elevated, resulting in rapid cell growth and stimulation of cell 
adhesion and invasion.
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Figure 20. Analysis for miR-27b hostgene APO
(a) RT-PCR analysis for APO and GAPDH. Csk-/- MEFs stably expressing pRetroX-Tet3G vector and 
pRetroX-TRE3G-c-Src were treated with Doxycycline (1µg/ml final) and total RNAs of the cells were 
collected after the indicated time. The graph shows the expression levels of APO estimated from the pictures 
using Image J. Data presented are shown as means ± s.d. from three independent experiments. (b) Real time-
PCR analysis for APO in breast normal (MCF10A) and cancer cells (T47D, MCF7 and MDA-MB-231). **P 
< 0.01, ***P<0.001. (c) Western blotting for APO. (d) Soft-agar colony-formation assay. MCF7 cells stably 
expressing empty vector (Mock) or pCX4-APO (APO#1, #2) were seeded in soft-agar. After a week, the 
number of colonies stained with MTT was counted on micrograph. **P < 0.01. (e) Wound healing assay. The 
cells indicated in (c) were plated on non-coated dishes the day before scratching. 24hrs after scratching, the 
closed area was quantitated from micrograph using Image J. 
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